BPC-157: Benefits, Dosage, Side Effects, and How to Get It in 2026
Medically reviewed by the Rite Aid Health Team · Last updated June 16, 2026
BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in gastric juice. It is the most-searched therapeutic peptide in the United States, and the most-studied for one reason: in animal research it accelerates the repair of tendon, ligament, muscle, and gut tissue.
It is also at the center of 2026's regulatory shift — in April the FDA removed it from the list that restricted compounding, and it is one of seven peptides under formal advisory review on July 23–24, 2026. New to peptides? Start with our peptide therapy guide.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
What is BPC-157?
BPC-157 is a stable fragment of a protein (Body Protection Compound) naturally present in human gastric juice. The synthetic peptide is a chain of 15 amino acids.
It does not occur in this isolated form in nature; it was developed to concentrate the tissue-protective activity researchers observed in the parent compound.
Benefits and uses
What the research shows — most of it in animal models, which is the honest framing for BPC-157:
- Tendon, ligament, and muscle repair. The most-studied effect. BPC-157 promotes angiogenesis (new blood-vessel formation) and fibroblast activity, which speeds soft-tissue healing in animal injury models.
- Gut repair. Given its origin in gastric juice, BPC-157 has been studied for protecting and healing the gut lining, including in models of inflammatory bowel conditions and NSAID-induced damage.
- Inflammation. It modulates inflammatory signaling, which is part of why it's used alongside injuries.
- Tissue protection. Research has looked at protective effects on a range of tissues, but human clinical data remains limited.
The gap between the volume of anecdote and the volume of human evidence is real. BPC-157 has a large following based on animal research and user reports; rigorous human trials are limited. State that plainly rather than overselling.
How it works
BPC-157 appears to act largely by promoting angiogenesis — the growth of new blood vessels into damaged tissue — and by upregulating growth-hormone receptor expression in injured tissue, which sensitizes the area to the body's own repair signals.
It also interacts with the nitric-oxide pathway, which contributes to its effects on blood flow and tissue protection.
Dosage and administration
Typical protocols in the literature and clinical practice use subcutaneous injection near the injury site, though oral and intramuscular routes are also used.
Commonly cited ranges run 200–500 mcg per dose, once or twice daily, in cycles of 4–6 weeks. These are not official dosing guidelines — there is no FDA-approved BPC-157 product — and dosing should be set by the prescribing provider.
Reconstitution (mixing the lyophilized powder with bacteriostatic water) and drawing the right volume on an insulin syringe is where most people make errors.
Use the peptide dosage calculator to convert your target dose into syringe units for your vial size.
Side effects and safety
BPC-157 has shown a favorable safety profile in animal studies, with low toxicity even at high doses. Reported effects in human use are generally mild — injection-site reactions, lightheadedness, fatigue, nausea.
The honest caveat: long-term human safety data does not exist. Anyone using BPC-157 should monitor liver enzymes and kidney function and work with a provider.
How to get BPC-157 in 2026
This is the question most searchers actually have. The status changed this year:
- For several years BPC-157 sat on the FDA's Section 503A Category 2 list, which effectively blocked compounding pharmacies from preparing it.
- On April 15, 2026 the FDA removed BPC-157 (and 11 other peptides) from that Category 2 list.
- A Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 will evaluate whether BPC-157 should be formally added to the authorized bulk-substances list compounding pharmacies can use.
Until that process completes, the cleanest legal route is a prescription filled by a licensed compounding pharmacy. Products sold online "for research use only" are not manufactured or quality-controlled for human use, and buying them carries both quality and legal risk.
Rite Aid is preparing compounded peptide consultations. Join the waitlist to claim 20% off your first BPC-157 order when consultations and ordering open.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
BPC-157 and TB-500
BPC-157 is frequently paired with TB-500 (a thymosin beta-4 fragment) for recovery. The rationale: BPC-157 drives angiogenesis and local repair, while TB-500 supports cell migration and broader soft-tissue regeneration. They are commonly run together in a recovery cycle.
For the broader recovery protocol, compare BPC-157 with other healing and recovery peptides, and see KPV for the anti-inflammatory addition.
Blood work to track BPC-157
BPC-157 doesn't have a single direct biomarker, so tracking focuses on the inflammation it's meant to reduce and on safety:
- hs-CRP — a sensitive inflammation marker; useful to see whether systemic inflammation is trending down.
- Comprehensive metabolic profile — liver enzymes and kidney function, the safety baseline for any peptide cycle.
Test before you start and again at 4–6 weeks.
Baseline tests before a peptide cycle
Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.
FAQ
Most commonly for soft-tissue and gut healing — tendon, ligament, and muscle injuries, and gut-lining repair. The strongest evidence is in animal research; human clinical data is limited.
The FDA removed BPC-157 from the Category 2 list that restricted compounding in April 2026, and a July 2026 advisory meeting will review formal authorization. A prescription filled by a licensed compounding pharmacy is the cleanest legal route. "Research use only" products are not approved for human use.
Protocols commonly use 200–500 mcg subcutaneously, once or twice daily, in 4–6 week cycles, but there is no FDA-approved product or official dosing. Dosing should be set by a prescribing provider.
Reported effects are generally mild — injection-site reactions, fatigue, nausea, lightheadedness. Long-term human safety data does not exist, which is the main caution.
Yes — it's a common recovery pairing. BPC-157 drives local repair and angiogenesis; TB-500 supports cell migration and broader tissue regeneration.
For an acute injury, users often report effects within a 4–6 week cycle. Inflammatory markers like hs-CRP may shift within the first few weeks.